Search Results

You are looking at 31 - 40 of 135 items for :

  • "febrile neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, and Pankit Vachhani

in those who developed TLS. No significant association was found between Ven ramp up and TLS incidence. 42(37.8%) had known infections prior to starting HMA+Ven. 41 patients (36.9%) were diagnosed with febrile neutropenia; 36 (32.4%) had confirmed

Full access

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung, and Taewoong Choi

-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia

Full access

Eric J. Bow

consequences for patients . Cancer 2004 ; 100 ( Suppl ): 1995 – 2025 . 13 Bodey GP . The treatment of febrile neutropenia: from the Dark Ages to the present . Support Care Cancer 1997 ; 5 : 351 – 357 . 14 Schimpff SC Satterlee W

Full access

Jeffrey Crawford, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, David P. Steensma, Saroj Vadhan-Raj, Peter Westervelt, and Michael Westmoreland

Overview Neutropenia (< 500 neutrophils/mcL or < 1000 neutrophils/mcL and a predicted decline to < 500/mcL over the next 48 hours) and resulting febrile neutropenia (≥ 38.3°C orally or ≥ 38.0°C over 1 hour) can be induced by myelosuppressive

Full access

Brahm H. Segal and Alison G. Freifeld

-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP

Full access

Jeremy Lund, Angela Pearson, and Georgia Keriazes

readmitting diagnosis or ICD-9 code. Criteria for CRR included diagnosis of febrile neutropenia, other known toxicity of administered chemotherapy agent, and documented diagnosis of CRR by the oncologist. A multidisciplinary panel (medical oncologist, oncology

Full access

Gary H. Lyman

a prospective nationwide study of oncology practice . J Natl Compr Canc Netw 2008 ; 6 : 109 – 118 . 2 Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer

Full access

Samuel L. Aitken, Jerod L. Nagel, Lilian Abbo, William Alegria, Jason N. Barreto, Sanjeet Dadwal, Alison G. Freifeld, Rupali Jain, Steven A. Pergam, Frank P. Tverdek, Susan K. Seo, and on behalf of the Antimicrobial Stewardship in Cancer Consortium ASCC

, immunotherapy). Safety of Antimicrobial De-escalation in Patients With Febrile Neutropenia Retrospective studies suggest that antibiotic de-escalation to fluoroquinolone prophylaxis in patients with febrile neutropenia who have defervesced and remain clinically

Full access

Gary H. Lyman

The 2019 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Growth Factors include appropriate risk assessment for febrile neutropenia following chemotherapy that is similar to other guidelines in different cancers. In

Full access

Gary H. Lyman and David C. Dale

complications, including febrile neutropenia, infection, and infection-related mortality, in patients undergoing cancer chemotherapy, while enabling an increase in delivered chemotherapy dose intensity. 1 , 2 Clinical practice guidelines from NCCN, ASCO, and